The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine

J Clin Pharmacol. 2006 Jun;46(6):628-34. doi: 10.1177/0091270006287024.


Ticlopidine is sometimes coadministered with ergoloid mesylates or ginkgo biloba in clinical situations. Our objective was to examine the effect of ergoloid mesylates and ginkgo biloba on ticlopidine pharmacokinetics. Ticlopidine, ergoloid mesylates, and ginkgo biloba significantly inhibited the organic anion transporting polypeptide (OATP-B)-mediated uptake of [(3)H]-estrone-3-sulfate in a concentration-dependent manner. When ergoloid mesylates was coadministered with ticlopidine, the ticlopidine area under the plasma drug concentration-time profile (AUC) from 0 to 12 hours was decreased 30% and the peak plasma drug concentration (C(max)) was decreased 29%, compared with ticlopidine administration alone. There were no significant changes in the pharmacokinetic parameters of ticlopidine when it was coadministered with ginkgo biloba. In summary, ergoloid mesylates is a more potent inhibitor of OATP-B than is ginkgo biloba, and it can reduce the oral bioavailability of drugs transported by OATP-B. Ergoloid mesylates markedly decreased the AUC and C(max) of ticlopidine, probably by inhibiting the OATP-B-mediated uptake of ticlopidine during the intestinal absorption phase. The results support a new model of intestinal drug-drug interaction.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cell Line
  • Drug Interactions
  • Ergoloid Mesylates / pharmacology
  • Estrone / analogs & derivatives
  • Estrone / metabolism
  • Female
  • Ginkgo biloba*
  • Humans
  • Intestinal Absorption / drug effects
  • Male
  • Organic Anion Transporters / metabolism*
  • Plant Preparations / pharmacology
  • Platelet Aggregation Inhibitors / blood
  • Platelet Aggregation Inhibitors / pharmacokinetics*
  • Ticlopidine / blood
  • Ticlopidine / pharmacokinetics*


  • Organic Anion Transporters
  • Plant Preparations
  • Platelet Aggregation Inhibitors
  • SLCO2B1 protein, human
  • Estrone
  • Ergoloid Mesylates
  • Ticlopidine
  • estrone sulfate